Why Achillion Pharmaceuticals Is Crashing 36% Today

Why Achillion Pharmaceuticals Is Crashing 36% Today

What happened After updating investors on its third-quarter performance and reporting that it’s still looking for a safe dose of ACH-4471 — an oral complement factor D drug — to study further, shares in Achillion Pharmaceuticals (NASDAQ:ACHN) are nose-diving 36% today. So what Achillion Pharmaceuticals licensed its hepatitis C drug pipeline to Johnson & Johnson → Read More

3 Numbers From Pengrowth Energy's Q3 Report That Investors Won't Want to Miss

3 Numbers From Pengrowth Energy's Q3 Report That Investors Won't Want to Miss

Pengrowth Energy (NYSE:PGH) has one aim this year: Survive to thrive. To achieve that objective, the company is pushing down costs to squeeze out as much cash flow as it can, which it intends to use on debt reduction. During the third quarter, Pengrowth made some progress on each goal, though it still has a long → Read More

Why Energy Recovery, Inc. Stock Dropped 15%

Why Energy Recovery, Inc. Stock Dropped 15%

What happened Energy Recovery (NASDAQ:ERII) manufactures industrial equipment for the fracking and desalination industries — two areas that you’d expect to be growing briskly in the modern environment of water shortages, and an energy industry reliant on fracking for oil and gas production. Unfortunately, things aren’t working out quite as planned. Last night, Energy Recovery → Read More

LinkedIn Stock Still Might Be the Best Buy in Tech

LinkedIn Stock Still Might Be the Best Buy in Tech

When investing in the stock market, there’s no such thing as a sure thing. However, LinkedIn‘s (NYSE:LNKD) soon-to-be-acquired stock appears to offer as close to a “free lunch” as is possible in the stock market today. Let’s explore the interesting investing scenario in LinkedIn’s stock today, why it exists, and a few additional important considerations → Read More

The 3 Best-Run Companies in the Automotive Sector

The 3 Best-Run Companies in the Automotive Sector

What are the best-run companies in the automotive sector?  Near-term concerns about auto sales have pushed prices of many auto companies’ stocks down to value levels. But not all value-priced companies are good buys. Genuine value stocks, the ones worth holding for a long time, have great management teams that position their companies for future → Read More

3 Important Things You Need to Know About Repligen Corporation's Q3 Results

3 Important Things You Need to Know About Repligen Corporation's Q3 Results

It’s been an up-and-down year so far in 2016 for Repligen Corporation (NASDAQ:RGEN). Repligen’s stock price is close to where it was in January despite plenty of big moves along the way. The bioprocessing company announced its third-quarter results before the market opened on Thursday. Are things looking more up than down for Repligen now? Here’s → Read More

Why Shares of Metaldyne Performance Group Are Soaring 41% Higher

Why Shares of Metaldyne Performance Group Are Soaring 41% Higher

What happened What a morning for investors of Metaldyne Performance Group Inc. (NYSE:MPG), a provider of engineered components for use in powertrain and suspension applications for the global light, commercial and industrial vehicle markets. Its shares are soaring 41% higher as of 11:20 a.m. EDT after the company released third-quarter results and revealed it would → Read More

Can Disney Follow the Lead of Cedar Fair and Six Flags?

Can Disney Follow the Lead of Cedar Fair and Six Flags?

We’re starting to see earnings reports trickle in from the operators behind some of the country’s largest theme parks and regional amusement parks. Shares of Cedar Fair (NYSE:FUN) moved 4% higher yesterday — bucking the market’s downward trend — after posting financial results for the seasonally beefy third quarter.  It wasn’t a blowout performance. Net → Read More

Why Shares of Sequential Brands Tumbled Today

Why Shares of Sequential Brands Tumbled Today

What happened Shares of apparel licensing and brand management company Sequential Brands (NASDAQ:SQBG) plunged on Thursday following a mixed third-quarter report. While revenue came in a bit higher than expected, guidance for full-year earnings was slashed. At 11:20 a.m. EDT, the stock was down about 32%. So what Third-quarter revenue soared 83% year over year → Read More

Why Pacific Biosciences Shares Are Falling 15.4% Today

Why Pacific Biosciences Shares Are Falling 15.4% Today

What happened Following third-quarter results that raised questions over whether the company will meet its full-year target for orders for its next-generation gene-sequencing machine, the Sequel, shares in Pacific Biosciences (NASDAQ:PACB) are down 15.4% at 11:30 a.m. EDT on Thursday.  So what Demand for Pacific Biosciences’ Sequel remains strong; however, during the company’s third-quarter conference call, VP of → Read More

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.